

# Special Issue

## DNA Methylation in Cancer

### Message from the Guest Editors

DNA methylation alterations underlie the carcinogenic process from its earliest stages. This is characterized by global losses of DNA methylation coupled with localized ectopic gains of DNA methylation at CpG islands, which are frequently associated with gene expression changes. A homeostatic balance between heterochromatin and euchromatin is essential to genomic stability. This Special Issue will give an overview of the various aspects that these epigenetic changes represent in cancer. Topics of interest will include but are not limited to the following: potential biomarkers for early detection and important prognostic and predictive markers to improve therapeutic interventions; the detection of these biomarkers through less invasive or noninvasive procedures; new therapeutic approaches based on epigenetic reprogramming; improved knowledge of the cellular processes affected by such early changes in the context of future functional studies.

---

### Guest Editors

Dr. Patrizia Zavattari  
Dr. Eleonora Loi  
Dr. Sergio Alonso

---

### Deadline for manuscript submissions

closed (15 July 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/78160](https://mdpi.com/si/78160)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)